Jon Kroll Bjerregaard

1.5k total citations
49 papers, 1.1k citations indexed

About

Jon Kroll Bjerregaard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jon Kroll Bjerregaard has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Surgery. Recurrent topics in Jon Kroll Bjerregaard's work include Pancreatic and Hepatic Oncology Research (18 papers), Colorectal Cancer Treatments and Studies (12 papers) and Gastric Cancer Management and Outcomes (11 papers). Jon Kroll Bjerregaard is often cited by papers focused on Pancreatic and Hepatic Oncology Research (18 papers), Colorectal Cancer Treatments and Studies (12 papers) and Gastric Cancer Management and Outcomes (11 papers). Jon Kroll Bjerregaard collaborates with scholars based in Denmark, Norway and United Kingdom. Jon Kroll Bjerregaard's co-authors include Per Pfeiffer, Benny Vittrup Jensen, Michael Bau Mortensen, Niels Henrik Holländer, Julia S. Johansen, Svend Erik Nielsen, Mette Yilmaz, Stig E. Bojesen, Kurt Buchmann and Dan Calatayud and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jon Kroll Bjerregaard

48 papers receiving 1.1k citations

Peers

Countries citing papers authored by Jon Kroll Bjerregaard

Since Specialization

Citations

This map shows the geographic impact of Jon Kroll Bjerregaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Kroll Bjerregaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Kroll Bjerregaard more than expected).

Fields of papers citing papers by Jon Kroll Bjerregaard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Kroll Bjerregaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Kroll Bjerregaard. The network helps show where Jon Kroll Bjerregaard may publish in the future.

Co-authorship network of co-authors of Jon Kroll Bjerregaard

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Kroll Bjerregaard. A scholar is included among the top collaborators of Jon Kroll Bjerregaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Kroll Bjerregaard. Jon Kroll Bjerregaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer 2020 ·European Journal of Cancer ·(unknown), Mette Yilmaz, Sture Falkmer, Laurids Østergaard Poulsen, Martin Bøgsted, (unknown), Stig E. Bojesen, Benny Vittrup Jensen, Inna M. Chen, Astrid Z. Johansen, Carsten Palnæs Hansen, Jane Preuss Hasselby, Niels Henrik Holländer, Svend Erik Nielsen, (unknown), Jon Kroll Bjerregaard, Per Pfeiffer, Julia S. Johansen	19
2	Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer 2019 ·Cancer Epidemiology Biomarkers & Prevention ·Inna M. Chen, Astrid Z. Johansen, Christian Dehlendorff, Benny Vittrup Jensen, Stig E. Bojesen, Per Pfeiffer, Jon Kroll Bjerregaard, Svend Erik Nielsen, (unknown), Niels Henrik Holländer, Mette Yilmaz, (unknown), Julia S. Johansen	12
3	Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma 2019 ·European Journal of Cancer ·Lars Bastholt, Henrik Schmidt, Jon Kroll Bjerregaard, Jørn Herrstedt, Inge Marie Svane	25
4	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma 2018 ·Cancer Chemotherapy and Pharmacology ·Stine Brændegaard Winther, Jon Kroll Bjerregaard, (unknown), (unknown), Merete Krogh, (unknown), Per Pfeiffer	6
5	Incidence of pancreatic cancer in Denmark: 70 years of registration, 1943–2012 2017 ·Acta Oncologica ·(unknown), Jon Kroll Bjerregaard, (unknown), Mogens Vyberg, Carsten Palnæs Hansen, Niels Henrik Holländer, Christoffer Johansen	9
6	Chemotherapy for patients with non-resectable pancreatic cancer with additional chemo-radiotherapy for patients with potentially resectable tumours: Final results 2016 ·Annals of Oncology ·Per Pfeiffer, Morten Ladekarl, Michael Bau Mortensen, (unknown), Jon Kroll Bjerregaard	2
7	Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980–2012 2016 ·Acta Oncologica ·Jon Kroll Bjerregaard, Michael Bau Mortensen, Per Pfeiffer	23
8	S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies 2016 ·Acta Oncologica ·Per Pfeiffer, Camilla Qvortrup, Merete Krogh, (unknown), Lene Weber Vestermark, (unknown), Jon Kroll Bjerregaard	3
9	Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group 2015 ·Clinical Colorectal Cancer ·Per Pfeiffer, (unknown), Camilla Qvortrup, (unknown), Christian Kersten, Kirsten Vistisen, Birgitta Lindh, Jon Kroll Bjerregaard, Bengt Glimelius	23
10	Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer 2013 ·PLoS ONE ·Nicolai A. Schultz, Ib Jarle Christensen, Jens Werner, Nathalia A. Giese, Benny Vittrup Jensen, Ole Larsen, Jon Kroll Bjerregaard, Per Pfeiffer, Dan Calatayud, Svend Erik Nielsen, Mette Yilmaz, Niels Henrik Holländer, Morten Wøjdemann, Stig E. Bojesen, Kaspar René Nielsen, Julia S. Johansen	29
11	Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer 2013 ·Acta Oncologica ·(unknown), Michael Bau Mortensen, Jon Kroll Bjerregaard, Claus Wilki Fristrup, Per Pfeiffer	6
12	Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer 2012 ·European Journal of Cancer ·(unknown), (unknown), Jon Kroll Bjerregaard, (unknown), Per Pfeiffer	18
13	Prognostic Factors for Survival and Resection in Patients With Initial Nonresectable Locally Advanced Pancreatic Cancer Treated With Chemoradiotherapy 2011 ·International Journal of Radiation OncologyBiologyPhysics ·Jon Kroll Bjerregaard, Michael Bau Mortensen, (unknown), Morten Nielsen, Per Pfeiffer	12
14	Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer 2011 ·Acta Oncologica ·Finn Ole Larsen, Per Pfeiffer, Dorte Nielsen, (unknown), Camilla Qvortrup, Kirsten Vistisen, (unknown), Trine Lembrecht Jørgensen, Jon Kroll Bjerregaard, (unknown), Benny Vittrup Jensen	11
15	Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum 2011 ·Gastric Cancer ·(unknown), Jon Kroll Bjerregaard, Tine Plato Hansen, Karin de Stricker, Morten F. Gjerstorff, (unknown), Lene Weber Vestermark, Per Pfeiffer	16
16	Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer 2010 ·Acta Oncologica ·Camilla Qvortrup, Benny Vittrup Jensen, Trine Lembrecht Jørgensen, Dorte Nielsen, Jon Kroll Bjerregaard, Per Pfeiffer	9
17	Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. 2009 ·PubMed ·Per Pfeiffer, Camilla Qvortrup, Jon Kroll Bjerregaard	3
18	The Effect of Aromatase Inhibitors on Bone Metabolism 2008 ·Basic & Clinical Pharmacology & Toxicology ·Lars Folkestad, Nina H. Bjarnason, Jon Kroll Bjerregaard, Kim Brixen	22
19	Treatment of Pseudodactylogyrus infestations of Anguilla anguilla. I. Trials with niclosamide, toltrazuril, phenolsulfonphthalein and rafoxanide. 1990 ·Bulletin of the European Association of Fish Pathologists ·Kurt Buchmann, Csaba Székely, Jon Kroll Bjerregaard	7
20	Treatment of Pseudodactylogyrus infestations of Anguilla anguilla. II. Trials with bunamidine, praziquantel and levamizole. 1990 ·Bulletin of the European Association of Fish Pathologists ·Kurt Buchmann, Csaba Székely, Jon Kroll Bjerregaard	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact